Advances in Surgery and (Neo) Adjuvant Therapy in the Management of Pancreatic Cancer
Hematology/Oncology Clinics of North America, ISSN: 0889-8588, Vol: 38, Issue: 3, Page: 629-642
2024
- 5Citations
- 3Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations5
- Citation Indexes5
- CrossRef2
- Captures3
- Readers3
Review Description
A multimodality approach, which usually includes chemotherapy, surgery, and/or radiotherapy, is optimal for patients with localized pancreatic cancer. The timing and sequence of these interventions depend on anatomic resectability and the biological suitability of the tumor and the patient. Tumors with vascular involvement (ie, borderline resectable/locally advanced) require surgical reassessments after therapy and participation of surgeons familiar with advanced techniques. When indicated, venous reconstruction should be offered as standard of care because it has acceptable morbidity. Morbidity and mortality of pancreas surgery may be mitigated when surgery is performed at high-volume centers.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0889858824000042; http://dx.doi.org/10.1016/j.hoc.2024.01.004; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85186629558&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/38429197; https://linkinghub.elsevier.com/retrieve/pii/S0889858824000042; https://dx.doi.org/10.1016/j.hoc.2024.01.004
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know